Endsulin
Thomas J Dee serves as the Chairman and CEO of Endsulin since October 2020, where Thomas J also holds the position of Chairman of the Board and serves as a Board Member for AirAnswers. Since June 2014, Thomas has been an independent business consultant and private investor, focusing on sectors such as healthcare services, biotech, and medical devices. Prior roles include Senior Vice President and Chief Financial Officer at AveXis, Inc. from August 2015 to October 2017, and various leadership positions at Abbott from January 1990 to September 2013, encompassing finance and audit functions. Thomas began their career as a Senior Auditor at Arthur Andersen & Co. and later worked as Corporate Cash Manager at Carson Pirie Scott. Thomas holds an MBA from Northwestern University’s Kellogg School of Management and a BS in Accounting from Northern Illinois University.
This person is not in any teams
Endsulin
Endsulin is a pre-clinical stage gene therapy company whose mission is to end insulin dependence for good and free people from being defined by diabetes. Our approach employs a widely studied and proven viral vector to deliver our patented genetic factor to the liver and restore the body’s own ability to produce and regulate insulin. With a single administration, Endsulin’s revolutionary genetic therapy for T1DM delivers a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin. Founded by an award-winning transplant surgeon and world leader in diabetes care and supported by a team of experts in gene therapy, endocrinology, diabetes science, and pharmaceutical development, Endsulin has the scientific, medical, and commercial expertise to develop its innovative therapy quickly, filling an enormous unmet need and bringing us one step closer to ending insulin dependence for good — and for the good of everyone with T1DM.